[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628255":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":32,"collaborators":10,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":10,"eligibilityCriteria":42,"healthyVolunteers":43,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":10,"studyType":50,"phases":10,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":20,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Elazığ Mental Health and Diseases Hospital","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Methamphetamine-Induced Psychotic Disorder (MP)",null,"Adult male participants (18-65 years) diagnosed with Methamphetamine-Induced Psychotic Disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5-TR) criteria. No intervention was\u002Fwill be assigned by the study protocol. At baseline, participants completed\u002Fwill complete a sociodemographic and clinical information form. Psychiatric symptoms and addiction-related characteristics will be assessed using standardized psychometric scales. Participants were followed\u002Fwill then be followed prospectively for twelve months. Participants will be contacted monthly to complete the same clinical assessments. The scales used\u002Fwill be used in this study are as follows: Morisky Medication Adherence Scale, Multidimensional Scale of Perceived Social Support, Insight Assessment Scale, Addiction Profile Index Clinical-Practitioner Form, Positive and Negative Syndrome Scale, Global Assessment Scale.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Mehmet Hamdi ÖRÜM, MD, Assoc. Prof., Psychiatrist","CONTACT","+905382207558","mhorum@hotmail.com",[19],{"facility":5,"status":20,"city":21,"state":21,"zip":22,"country":23,"countryCode":10,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"RECRUITING","Elâzığ","23200","Turkey (Türkiye)",{"type":25,"coordinates":26},"Point",[27,28],39.22321,38.67431,{"lat":28,"lon":27},[31],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"type":33,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Mehmet Hamdi ÖRÜM","Associate Professor, MD, Psychiatrist","100628255","psychiatric-symptom-predictors-in-methamphetamine-induced-psychosis-100628255",false,"NCT07459257","Psychiatric Symptom Predictors in Methamphetamine-Induced Psychosis","Investigation of Factors Associated With Psychiatric Symptoms in Methamphetamine-Induced Psychotic Disorder: One-Year Longitudinal Study","* Methamphetamine-Induced Psychotic Disorder (MP) Group:\n\n  \\*Inclusion Criteria:\n  * Diagnosis of MP according to DSM-5-TR\n  * Medication-free for at least one month prior to admission\n  * Age ≥ 18 years and \\\u003C65 years\n  * Provided informed consent\n* Methamphetamine-Induced Psychotic Disorder (MP) Group:\n\n  * Exclusion Criteria:\n\n    * Hypertension\n    * Diabetes mellitus\n    * Chronic kidney disease\n    * Rheumatoid arthritis\n    * Systemic lupus erythematosus\n    * Cardiac illness\n    * Severe neurological disorders\n    * Immunological or systemic illness\n    * Primary psychiatric disorders other than MP\n    * Alcohol use disorder",true,"MALE","18 Years","65 Years",{"count":48,"type":49},150,"ESTIMATED","OBSERVATIONAL","This longitudinal observational study aimed to investigate environmental, familial, and individual factors associated with psychiatric symptom severity in participants diagnosed with methamphetamine-induced psychotic disorder (MP). Participants diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5-TR) criteria was followed\u002Fwill be followed prospectively for one year. Sociodemographic characteristics, treatment adherence, perceived social support, addiction-related clinical variables, insight levels, and psychotic symptoms was assessed\u002Fwill be assessed monthly using standardized psychometric instruments.\n\nThe study aimed to identify predictors associated with relapse-remission patterns and changes in psychiatric symptoms over a one-year follow-up period.",[53],"Methamphetamine Induced Psychosis",[55,56,57,58,59],"Methamphetamine","Methamphetamine-Induced Psychosis","Psychiatric Symptoms","Methamphetamine-Induced Psychotic Disorder","Longitudinal Study","2026-03-04",{"date":62,"type":63},"2026-03-09","ACTUAL",{"date":65,"type":63},"2025-02-03",{"date":67,"type":49},"2026-08-17",{"name":5,"class":6},1]